Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Metastatic Malignant Solid NeoplasmUnresectable Malignant Solid Neoplasm
Interventions
PROCEDURE

Biopsy Procedure

Undergo biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Computed Tomography

Undergo CT scan

PROCEDURE

Echocardiography Test

Undergo echocardiography

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA scan

DRUG

Neratinib Maleate

Given PO

BIOLOGICAL

Trastuzumab Deruxtecan

Given IV

Trial Locations (18)

15232

RECRUITING

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

32610

RECRUITING

University of Florida Health Science Center - Gainesville, Gainesville

40536

RECRUITING

University of Kentucky/Markey Cancer Center, Lexington

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

53718

RECRUITING

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison

53792

RECRUITING

University of Wisconsin Carbone Cancer Center - University Hospital, Madison

60611

RECRUITING

Northwestern University, Chicago

63110

RECRUITING

Washington University School of Medicine, St Louis

77030

RECRUITING

M D Anderson Cancer Center, Houston

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

91030

RECRUITING

City of Hope South Pasadena, South Pasadena

91786

RECRUITING

City of Hope Upland, Upland

92612

RECRUITING

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine

92618

RECRUITING

City of Hope at Irvine Lennar, Irvine

92868

RECRUITING

UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange

93534

RECRUITING

City of Hope Antelope Valley, Lancaster

95817

RECRUITING

University of California Davis Comprehensive Cancer Center, Sacramento

02215

RECRUITING

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH